Hematological Disorders

Treating Iron Deficiency Anemia in Patients With Inflammatory Bowl Disorder

By October 19, 2017

Despite its frequency, iron deficiency anemia in patients with IBD it is often overlooked in clinical settings.

Blood Transfusions from Ever-Pregnant Donors and Recipient Mortality: What's the Link?

October 18, 2017

Receipt of red blood cell transfusion from ever-pregnant donor tied to increased risk for males.

Thromboembolic Disorder Treatments: Without DVT/PE

October 16, 2017

A comparative medication chart of thromboembolic disorder treatments in patients without DVT/PE.

Anticoagulants Taken With Certain Meds May Up Bleeding Risk

October 05, 2017

And antithrobotic medications linked to higher rate of hematuria-related events in older adults

Recall of Erythropoiesis-Stimulating Agent Expanded

By September 26, 2017

The recall is due to the finding of glass flakes (lamellae) observed in 2 additional Lots during a routine inspection.

Phase 3 Results Announced for Lusutrombopag for Thrombocytopenia

By September 25, 2017

The trial, L-PLUS2, included 215 patients who were randomized 1:1 to either 3mg of lusutrombopag or placebo for up to 7 days.

NDA Submitted for Thrombocytopenia Treatment

By September 22, 2017

The results from Phase 3 trials demonstrated efficacy and safety in patients with severe thrombocytopenia and with CLD.

Hemotopoietic Stem Cell Transplant Examined for Inherited Blood Disorder

September 13, 2017

The researchers found that in transplanted patients, the 30-year overall survival (OS) was 82.6±2.7% and thalassemia-free survival (TFS) was 77.8±2.9% compared with OS of 85.3±2.7% in CT patients (P=NS).

Blood Disorder ID'd as Possible Reason for Vampire Folklore

By September 08, 2017

Erythropoietic protoporphyria (EPP), the most common form of porphyria (a group of blood disorders), affects the body's ability to make heme resulting in symptoms of chronic anemia. A patient's skin can become very sensitive to light, resulting in disfiguring blisters.

Aplastic Anemia Outcomes Examined for Anti-Thymoglobulin-Based IST

September 07, 2017

The researchers found that OS was superior in IST responders. Shorter relapse-free survival (RFS) was seen with partial response to IST compared with complete response.

Thromboembolic Disorder Assessment: DVT/PE

September 04, 2017

Risk factors, prevention strategies, signs & symptoms, and general treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE).

Thromboembolic Disorder Treatments: DVT/PE

September 04, 2017

List of medications indicated for the prophylaxis and/or treatment of deep vein thrombosis (DVT) / pulmonary embolism (PE) with usual adult dosage.

Anticoagulant Dosing Conversions

September 04, 2017

Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.

Prophylaxis vs. On Demand Tx in Patients with Severe Hemophilia

August 31, 2017

Overall, 35.7% of prophylaxis participants were bleed-free and 76.2% had fewer than 2 BEs per year.

BLA for Novel Hemophilia A Therapy Granted Priority Review

By August 24, 2017

The FDA has accepted and granted Priority Review to the Biologics License Application (BLA) of emicizumab (Genentech) for the prophylactic treatment of hemophilia A in adults, adolescents and children with factor VIII inhibitors.

BLA Submitted for Novel X-Linked Hypophosphatemia Tx

By August 24, 2017

Burosumab is being developed in a collaboration between Ultragenyx and Kyowa Hakko Kirin Pharmaceuticals, based on a license agreement between both companies.

ESA Agent Recalled Due to Presence of Particulate in Vials

By August 22, 2017

Healthcare professionals are urged to following the package insert instructions regarding careful inspection of vials.

FDA Approves Additional Vial Strengths of Nuwiq for Hemophilia A

By August 22, 2017

In addition to the currently available strengths (250, 500, 1000, 2000 IU), starting in September, Nuwiq will also be supplied in 2500, 3000, and 4000 IU vial strengths.

Novel Reversal Agent for Factor Xa Inhibitors Under FDA Review

By August 17, 2017

The FDA has accepted for review the BLA resubmission for AndexXa (andexanet alfa; Portola) for the reversal of the anticoagulant effects of Factor Xa inhibitors in patients experiencing uncontrolled or life-threatening bleeding.

'Groundbreaking' Technology Heals Serious Injuries with a Single Touch

By August 09, 2017

"By using our novel nanochip technology, injured or compromised organs can be replaced. We have shown that skin is a fertile land where we can grow the elements of any organ that is declining," said Dr. Chandan Sen.

Angioedema Risk Assessed for Aliskiren vs. Other Antihypertensives

By August 07, 2017

The case-control analysis found no significant difference in the angioedema risk for aliskiren monotherapy and fixed-dose combination compared to BBs with adjusted odds ratio of 0.99 (95% CI, 0.45-2.20) and 1.06 (0.40-2.76), respectively.

Investigational PNH Treatment Granted Orphan Drug Status

By August 04, 2017

"We have designed RA101495 for once-daily, subcutaneous self-administration, an approach which has the potential to ease this burden, improve convenience, and provide much-needed dosing flexibility," said Doug Treco, PhD, President and CEO of Ra Pharma.

Investigational PNH Treatment Granted Orphan Drug Status

By August 04, 2017

"We have designed RA101495 for once-daily, subcutaneous self-administration, an approach which has the potential to ease this burden, improve convenience, and provide much-needed dosing flexibility," said Doug Treco, PhD, President and CEO of Ra Pharma.

Caplacizumab Fast-Tracked for Acquired Thrombotic Thrombocytopenic Purpura

By July 26, 2017

The Phase 2 TITAN study (n=75) evaluated the safety and efficacy of caplacizumab with standard of care of plasma exchange and immunosuppression.

Angioedema Risk Evaluated for Levetiracetam Versus Phenytoin

By July 25, 2017

"The results suggest that levetiracetam has the same or lower risk for angioedema than phenytoin," wrote the researchers.

Haegarda Available for Routine Prophylaxis of Hereditary Angioedema Attacks

By July 25, 2017

Haegarda reduced the number of HAE attacks by a median of 95% vs. placebo

Idarucizumab Effective for Dabigatran Reversal in Emergency Situations

July 13, 2017

Effective for dabigatran reversal among patients with uncontrolled bleeding, undergoing urgent surgery

Eculizumab Linked to High Risk of Meningococcal Disease, Despite Vaccination

By July 10, 2017

In vitro data have shown that eculizumab impairs meningococcal killing in whole blood despite patients being vaccinated against the appropriate serogroup. The current vaccines against meningococcal disease only target serogroup-specific proteins and do not provide protection against nongroupable N. meningitidis.

FDA Approves New Sickle Cell Disease Treatment

By July 07, 2017

The safety and efficacy of Endari were evaluated in a randomized clinical trial involving patients aged 5-58 years with sickle cell disease who had ≥2 painful crises within 12 months prior to trial enrollment.

Breckenridge Approved for Generic Vidaza

By June 29, 2017

Vidaza is indicated as treatment for myelodysplastic syndrome (MDS), specifically refractory anemias and chronic myelomonocytic leukemia; it can be given either subcutaneously (SC) or intravenously (IV).